Title: Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Authors: Palumbo, Antonio ×
Hajek, Roman
Delforge, Michel
Kropff, Martin
Petrucci, Maria Teresa
Catalano, John
Gisslinger, Heinz
Wiktor-Jedrzejczak, Wieslaw
Zodelava, Mamia
Weisel, Katja
Cascavilla, Nicola
Iosava, Genadi
Cavo, Michele
Kloczko, Janusz
Bladé, Joan
Beksac, Meral
Spicka, Ivan
Plesner, Torben
Radke, Joergen
Langer, Christian
Ben Yehuda, Dina
Corso, Alessandro
Herbein, Lindsay
Yu, Zhinuan
Mei, Jay
Jacques, Christian
Dimopoulos, Meletios A
MM-015 Investigators #
Issue Date: May-2012
Series Title: New England Journal of Medicine vol:366 issue:19 pages:1759-1769
Abstract: Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Non-KU Leuven Association publications
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science